Results 1 to 10 of about 296,086 (304)

Virus-like Particles: Measures and Biological Functions [PDF]

Viruses, 2022
Virus-like particles resemble infectious virus particles in size, shape, and molecular composition; however, they fail to productively infect host cells.
Tara Bhat, Amy Cao, John Yin
doaj   +4 more sources

Programmable polymorphism of a virus-like particle [PDF]

Communications Materials, 2022
Virus-like particles are promising for drug delivery systems and vaccine development, but controlling their size and morphology is challenging. Here, amino acid sequences are inserted into MS2 bacteriophage virus-like particles, with their size and shape
Artur P. Biela, Antonina Naskalska, Farzad Fatehi, Reidun Twarock, Jonathan G. Heddle   +4 more
doaj   +6 more sources

Characterization of chikungunya virus-like particles. [PDF]

PLoS ONE, 2014
Chikungunya virus (CHIKV) is becoming a global concern due to the increasing number of outbreaks throughout the world and the absence of any CHIKV-specific vaccine or treatment.
Nitchakarn Noranate, Naokazu Takeda, Prukswan Chetanachan, Pathompong Sittisaman, Atchareeya A-Nuegoonpipat, Surapee Anantapreecha   +5 more
doaj   +4 more sources

Platelet-like particles released from Ebola virus-infected megakaryocytic cells behave like virus-like particles. [PDF]

PLoS Pathogens
Ebola virus (EBOV) is likely a zoonotic and re-emerging virus that causes severe outbreaks of Ebola virus disease. The virus spreads to various tissues during the late stage of infection and has been detected in immune-privileged sites of survivors ...
Makoto Kuroda, Peter J Halfmann
doaj   +2 more sources

Virus-like particles in vaccine development

Expert Review of Vaccines, 2010
Virus-like particles (VLPs) are multiprotein structures that mimic the organization and conformation of authentic native viruses but lack the viral genome, potentially yielding safer and cheaper vaccine candidates. A handful of prophylactic VLP-based vaccines is currently commercialized worldwide: GlaxoSmithKline's Engerix (hepatitis B virus) and ...
Manuel J T Carrondo, Antonio Roldāo, Alves Pm   +2 more
exaly   +3 more sources

Colloidal Crystallization of Virus-Like Particles with Polycations. [PDF]

Small
Virus-like particles (VLPs) are protein nanocages capable of encapsulating or attaching guest molecules. Unlike viruses, they do not replicate in cells, making them promising candidates for advanced biomaterial design, particularly for biomedical applications such as drug delivery. However, the mechanisms governing VLP self-assembly into highly ordered
Tran B, Keys TG, Radiom M, Salentinig S.
europepmc   +4 more sources

Immunogenicity of Virus-like Particles Based on VP1 Protein of Bovine Norovirus [PDF]

Veterinary Sciences
Bovine Norovirus (BNoV) is a member of the enterovirus family that can cause gastroenteritis in calves. This virus poses a significant risk to calf growth and development as well as to the long-term sustainability of the cattle industry in China and ...
Zhigang Ma, Xuelian Ma, Xinyu Tao, Yong Huang, Qian Jiang, Xiaojun Ding, Fang Min, Yichen Chu, Ru Li, Xinying Zhang, Lu Liu, Caiyun Zhang, Qi Zhong, Gang Yao   +13 more
doaj   +2 more sources

Recent Progress on the Versatility of Virus-Like Particles

Vaccines, 2020
Virus-like particles (VLPs) are multimeric nanostructures composed of one or more structural proteins of a virus in the absence of genetic material. Having similar morphology to natural viruses but lacking any pathogenicity or infectivity, VLPs have ...
Ciying Qian, Xinlin Liu, Qin Xu, Zhiping Wang, Jie Chen, Tingting Li, Qingbing Zheng, Hai Yu, Ying Gu, Shaowei Li, Ningshao Xia   +10 more
doaj   +3 more sources

Production of virus-like particles for vaccines

New Biotechnology, 2017
Virus-like particles (VLPs) are nanostructures that resemble the structures of viruses. They are composed of one or more structural proteins that can be arranged in several layers and can also contain a lipid outer envelope. VLPs trigger a high humoral and cellular immune response due to their repetitive structures. A key factor regarding VLP safety is
Fuenmayor, J., Gòdia, F., Cervera, L.
exaly   +3 more sources

Size-selective downstream processing of virus particles and non-enveloped virus-like particles

Frontiers in Bioengineering and Biotechnology, 2023
Non-enveloped virus-like particles (VLPs) are versatile protein nanoparticles with great potential for biopharmaceutical applications. However, conventional protein downstream processing (DSP) and platform processes are often not easily applicable due to
Nils Hillebrandt, Jürgen Hubbuch
doaj   +1 more source